Converting one benzodiazepine into another looks like arithmetic until you watch it go wrong. Whether you are switching someone from lorazepam to diazepam before a planned taper, estimating what a patient is really taking, or answering a pharmacology stem in an exam, benzodiazepine equivalence conversion is the starting point — and knowing exactly where the approximation breaks down is what separates a safe plan from a hazardous one.

This article gives you the approximate diazepam-equivalent doses with their half-lives, the pharmacology that explains why the numbers move, a worked conversion, and the taper principles that examiners like to test. Treat the table as a memory aid and the caveats as the mark-scorers: equivalence tables are clinical estimating tools, never bioequivalence claims.

What benzodiazepine equivalence conversion means (and what it does not)

A benzodiazepine-equivalent dose answers one practical question: how much diazepam would produce roughly the same effect as this dose of this drug? Equivalence here means therapeutic interchange at the level of approximate potency — the dose needed to produce a comparable anxiolytic, hypnotic or anticonvulsant effect in a typical adult — not identical plasma levels, not identical receptor occupancy over time, and not interchangeable side-effect profiles.

Three pharmacological variables drive the differences:

  • Intrinsic potency at the GABA-A receptor. All benzodiazepine-site agonists potentiate chloride conductance, but they differ in µg-for-mg potency and in subunit selectivity, which is why alprazolam is dosed in fractions of a milligram and diazepam in tens.
  • Lipid solubility and active metabolites. Diazepam and chlordiazepoxide are highly lipophilic with long-lived active metabolites (desmethyldiazepam, oxazepam), so their apparent duration far outlasts their parent half-life. Lorazepam and oxazepam undergo direct glucuronidation with no active metabolites.
  • Metabolic route. CYP3A4 handles midazolam, triazolam and much of alprazolam; CYP2C19 handles diazepam and temazepam. Inhibitors such as clarithromycin or omeprazole can shift effective exposure in either direction.

That last point matters at the bedside: a "standard" conversion assumes normal hepatic function, normal protein binding, and no interacting drugs. Change those assumptions and the equivalence table degrades from a guide into a guess.

Approximate diazepam equivalents and half-lives

The values below are approximations synthesised from the Ashton manual (Ashton, 2002, University of Newcastle), the BNF entries for individual agents, and standard UK teaching. They describe a single approximate equivalent dose, not a range of bioequivalent exposures.

BenzodiazepineApprox. diazepam equivalentApprox. elimination half-lifeNotes
Diazepam10 mg20–100 h (with active metabolites)Reference drug; accumulates with repeated dosing
Lorazepam1 mg10–20 hNo active metabolites; predictable in liver disease
Alprazolam0.5 mg6–12 hShort acting; high withdrawal intensity reported
Clonazepam0.5–1 mg18–50 hAlso used as an anticonvulsant
Temazepam10–20 mg8–22 hSources vary; range reflects genuine disagreement
Nitrazepam10 mg15–38 hOlder hypnotic, marked next-day carryover
Chlordiazepoxide25 mg24–100 hAlcohol withdrawal workhorse; long metabolite tail

Two things to notice after any benzodiazepine equivalence conversion. First, the short-acting agents (alprazolam, midazolam) sit at one end of the range and produce the sharpest inter-dose withdrawal phenomena — the "rebound" that patients mistake for worsening anxiety. Second, the long-acting agents convert more forgivingly because their smooth pharmacokinetics blunt the peaks and troughs.

High-yield: equivalence tables are approximations, not bioequivalence

Examiners reward candidates who use a conversion table and say why it is approximate. Inter-individual variation in absorption, CYP activity, protein binding and receptor pharmacodynamics means two patients given "equivalent" doses are not bioequivalent — they may be a full dose-step apart in effect. Always write conversions as an estimate, build in review, and check the BNF for the drug in front of you rather than recalling a number from memory.

A worked conversion: lorazepam to diazepam

Take a patient established on lorazepam 1 mg three times daily. The arithmetic:

  1. Total daily lorazepam: 3 mg.
  2. Convert to diazepam equivalents: 1 mg lorazepam ≈ 10 mg diazepam, so 3 mg ≈ 30 mg diazepam per day.
  3. Choose a practical schedule: 30 mg daily as a single nighttime dose, or split 10 mg morning / 20 mg night if daytime anxiolysis matters and sedation is a concern.
  4. Account for the half-life: diazepam accumulates over 3–4 days to steady state. Do not chase early "under-treatment" with extra doses on day one.
  5. Review: reassess at 5–7 days, and expect to fine-tune by 2.5–5 mg rather than re-convert from scratch.

If the destination is withdrawal rather than substitution, the conversion is only step one. A patient on lorazepam 1 mg twice daily is a roughly 20 mg diazepam-equivalent daily consumer, and your taper plan is built from that number — which is why trainees are expected to convert fluently, in both directions. Our concept library covers GABAergic pharmacology with the same dose logic used here.

Tapering: the 10% rule and how slow is slow enough

There is no single validated taper schedule, but two frameworks dominate practice and it is worth knowing both.

  • Ashton-style gradual taper: reduce by roughly 10% of the current dose every 2–4 weeks, with longer holds once the patient passes below about half of the original dose, because receptor adaptation catches up more slowly at low doses. Total tapers for established high-dose users commonly run 6–12 months or longer.
  • NICE NG115 (drug misuse management): where dependence has developed, withdraw gradually over at least 2–4 weeks, extending the schedule for higher doses and for those with previous severe withdrawal or psychiatric comorbidity. The emphasis is on a written plan, regular review, and never stopping abruptly.

Practical points that recur in exams and OSCEs: halve the frequency before halving the dose where possible; hold the reduction if the patient develops new insomnia, tremor or perceptual symptoms; and do not substitute a dose reduction with alcohol, which is the commonest route back to relapse. Predominant symptoms after abrupt cessation — anxiety, insomnia, tremor, sweating, perceptual hypersensitivity, and in severe cases seizures and delirium — typically peak within the first 1–2 days for short-acting agents and 3–7 days for long-acting ones.

Flumazenil, overdose and other exam-relevant edges

Flumazenil is a competitive benzodiazepine-site antagonist with a short half-life (about 1 hour) and a correspondingly short duration of action. It reverses procedural sedation and can reverse neonatal respiratory depression, but it is not a routine antidote in benzodiazepine overdose: the half-life mismatch causes resedation, and in a chronically dependent patient it can precipitate acute withdrawal including seizures. That paradox — an antidote you withhold precisely because the drug is used chronically — is a classic question stem.

Cross-tolerance is worth one line of memory: because all benzodiazepines share a binding site, tolerance to one produces substantial cross-tolerance to the others. That is why equivalence tables can guide a switch, but why switching does not reset tolerance or permit a dose increase.

Frequently asked questions

How do you convert lorazepam to diazepam equivalents for a taper?

Multiply the total daily lorazepam dose by 10 to get an approximate daily diazepam-equivalent dose — so lorazepam 1 mg three times daily (3 mg/day) is approximately 30 mg of diazepam per day. Convert the total first, then choose a practical single or split dosing schedule, allow 3–4 days for diazepam to accumulate to steady state, and begin reductions from that estimated total using a roughly 10% per 2–4 week schedule.

Why is benzodiazepine equivalence conversion never exact?

Because equivalence is estimated from population-level potency, not measured bioequivalence in an individual. Absorption, CYP2C19/CYP3A4 activity, protein binding, liver function, concomitant interacting drugs, receptor subunit composition and prior exposure all vary between patients, so two people taking "equivalent" doses can differ by a full dose-step in clinical effect. Different published tables also disagree — temazepam equivalence is the commonest example, quoted as anything from 10 to 20 mg against diazepam 10 mg.

How much should you reduce a benzodiazepine dose at each step?

As a starting rule, reduce by about 10% of the current dose every 2–4 weeks, holding or slowing the taper whenever withdrawal symptoms emerge. NICE NG115 advises gradual withdrawal over at least 2–4 weeks for dependence in general terms, with slower schedules for high-dose users and those with previous severe withdrawal. The exact rate should be individualised and documented in a written plan.

When is flumazenil contraindicated in benzodiazepine overdose?

It is avoided or used with great caution in patients with chronic benzodiazepine dependence, because reversing the effect can precipitate acute withdrawal including seizure and delirium; in suspected co-ingestant overdose (tricyclics, stimulants) it can also unmask seizure risk by lowering the seizure threshold. Its short half-life further means patients resedate, so it has little role as definitive treatment of benzodiazepine poisoning itself.

Key takeaways

  • Diazepam 10 mg ≈ lorazepam 1 mg ≈ alprazolam 0.5 mg ≈ nitrazepam 10 mg ≈ chlordiazepoxide 25 mg — all as approximations, never as bioequivalence claims.
  • Half-life class drives the withdrawal pattern: short-acting agents cause sharper inter-dose rebound; long-acting agents taper more smoothly.
  • Convert the total daily dose first, choose the schedule second, and allow 3–4 days of accumulation before judging a switch.
  • Taper with roughly 10% reductions every 2–4 weeks, slowing below half the starting dose and pausing for emerging symptoms.
  • Flumazenil reverses procedural sedation but is not routine in overdose or in dependent patients — seizure and resedation risk.

If equivalence conversion and tapers are a weak area for you, that is exactly the kind of pharmacology the Preppsy MRCPsych curriculum maps into short, testable concept blocks you can revisit on a spacing schedule.

Cover image: “Benzodiazepine Equivalence (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.